Company Profile

LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. The company was formerly known as LegoChem Biosciences, Inc. and changed its name to LigaChem Biosciences Inc. in April 2024. LigaChem Biosciences Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.

Latest News

AECOM selected to design New Lisbon Airport

Business Wire • 07/27/2026

Christopher Nolan’s The Odyssey Continues its Journey in IMAX with Record-Breaking $48 Million Second Weekend

Business Wire • 07/27/2026

Ipsen’s Bylvay fails in Phase III biliary atresia study

Clinical Trials Arena • 07/27/2026

Rothschild & Co Redburn Adjusts PT on Honeywell International to $216 From $214, Keeps Neutral Rating

MT Newswires • 07/27/2026

JPMorgan Adjusts PT on Honeywell International to $262 From $250, Maintains Overweight Rating

MT Newswires • 07/27/2026